Compare UG & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UG | NEPH |
|---|---|---|
| Founded | 1942 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.9M | 31.0M |
| IPO Year | 1995 | 2004 |
| Metric | UG | NEPH |
|---|---|---|
| Price | $7.24 | $2.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 2.9K | ★ 21.6K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | ★ 7.10% | N/A |
| EPS Growth | N/A | ★ 1000.00 |
| EPS | ★ 0.20 | 0.11 |
| Revenue | $10,545,468.00 | ★ $18,789,000.00 |
| Revenue This Year | N/A | $11.24 |
| Revenue Next Year | N/A | $11.58 |
| P/E Ratio | $35.65 | ★ $29.36 |
| Revenue Growth | N/A | ★ 32.67 |
| 52 Week Low | $5.58 | $1.78 |
| 52 Week High | $9.88 | $6.42 |
| Indicator | UG | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 64.39 | 52.20 |
| Support Level | $6.26 | $2.79 |
| Resistance Level | $7.70 | $3.18 |
| Average True Range (ATR) | 0.18 | 0.24 |
| MACD | 0.05 | 0.06 |
| Stochastic Oscillator | 88.00 | 69.11 |
United-Guardian Inc manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products. Its product portfolio includes Klensoft, Deselex, Renacidin, Lubrajel Fluid. The company's pharmaceutical products are sold to and distributed by full-line drug wholesalers throughout the United States. Its medical and specialty industrial products are sold directly by the company to the end-users of those products or, in some cases, to contract manufacturers used by some of those end users. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. It derives key revenue from the sales made in the U.S.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.